Management team
Read more:
Management team
Andreas Bhagwani
Born 1975
CEO since 2011
andreas.bhagwani@nanologica.com
Education and training:
EMBA from Stockholm School of Economics, studies in agronomy at the Swedish University of Agricultural Sciences in Uppsala.
Main experience:
Andreas is the co-founder of several companies, the most recent being Sigrid Therapeutics AB (obesity therapy) and Atrogi AB (diabetes). Andreas has worked as a management consultant for over a decade, specializing in sales and leadership. In addition to the above companies, he is a co-founder of Kichisaga Leadership, GenderTimer and HIGS.
Other assignments:
CBoard member and owner of Vega Bianca AB. CEO and chairman of the board of Nanologica Black AB and Nanologica Yellow AB. Board member of Nanghavi AB and Nanghavi Chromatography Solutions Pvt Ltd, deputy board member and partner of Kichisaga Leadership AB. Holder of the individual firm Baraza Konsult.
Holdings:
Holds 2,017,264 shares through the company Vega Bianca AB, and 200,000 options (of the series 2021/2024).
Eva Osterman
Born 1971
CFO since 2017
eva.osterman@nanologica.com
Education and training:
Master of Science in Business Administration and Economics from Uppsala University.
Main experience:
Eva has several years of experience from the finance side at larger companies where Eva has worked with business controlling, financial controlling, reporting, and internal audit. She also has extensive experience from major international groups in, among others, the pharmaceutical industry.
Other assignments:
Board member of Nanghavi Chromatography Solutions Pvt Ltd and Nanologica Australia Pty. Ltd, deputy board member of Nanghavi AB, Nanologica Black AB, Nanologica Yellow AB and Consensor AB. Auditor in Rangsta Båtklubb.
Holdings:
51,283 shares, and 150,000 options (of the series 2021/2024).
Anna-Karin Renström
Born 1964
COO since 2019
EDUCATION AND TRAINING:
Master of Science in Industrial Economics from Linköping Linköping University of Technology, Executive Management Program, Stockholm School of Economics, Certification in Board work, Styrelsekraft via ALMI
MAIN EXPERIENCE:
Anna-Karin was the CEO of Telge Inköp for 10 years before joining Nanologica. She was also the chairman of Telge Kraft AB and board member at Telge Nät AB. Previously she has held various positions within purchasing and finance at AstraZeneca.
OTHER ASSIGNMENTS:
Board member of Avia Pharma Holding AB. Owner and board member of AKRR Konsult AB.
HOLDINGS:
Holds 48,483 shares.
Gary Pitcairn
Born 1967
Chief Scientific Officer since 2021
EDUCATION AND TRAINING:
BSc Biochemistry and Biological Chemistry, Univeristy of Nottingham. PhD University of Nottingham.
MAIN EXPERIENCE:
Gary is a recognised expert in inhaled drug delivery, with extensive device experience (DPI, pMDI and nebuliser). He has previously worked at Mylan, Pfizer and most recently AstraZeneca where he was Head of Project Leadership – Respiratory Pharmaceutical Technology & Development.
OTHER ASSIGNMENTS:
Board member of GRP Consulting AB.
HOLDINGS:
115,000 options (of the series 2021/2024).
Ulf Ericsson
Born 1966
VP Drug Development since 2021
Education and training:
Master of Science in Business Administration, Business Economics (BSc) and Marketing Management (MSc), Lund University
Main experience:
Ulf has more than 20 years of experience from leading marketing and business development positions in the respiratory field and inhalation, including formulation technology and development of inhalers. Ulf comes most recently from AstraZeneca where he has been active for a total of 17 years, including as Global Sr Director Respiratory Inhalation.
Other assignments:
Board member of Nanologica Australia Pty. Ltd
Holding:
2,861 shares and 115,000 options (of the series 2021/2024).
Katarina Alenäs
Born 1970
SVP Chromatography since 2022
Education and training:
Master of Science in Chemical Engineering at Lunds Tekniska Högskola and Bachelor of Science in Pharmaceutical Sciences at the University of Greenwich.
Main experience:
Katarina has extensive experience from the life science industry and comes most recently from 10 years with senior positions at Agilent Technologies in business development and sales, as well as 7 years as CEO of Agilent Sweden. Katarina has previously been product manager Shimadzu HPLC/LCMS and has worked as a product and method developer for Kromasil’s silica-based packaging media for preparative chromatography.
Other assignments:
Board member of Biotech i Kungsbacka AB.
Holding:
120,000 options (of the series 2021/2024).